Content deleted Content added
Bare URL removed |
Added short description Tags: Mobile edit Mobile app edit Android app edit App suggested edit App description add |
||
| (16 intermediate revisions by 5 users not shown) | |||
Line 1:
{{Short description|France-based pharmaceutical group}}
{{Infobox company
|name = Advanced Accelerator Applications
Line 9 ⟶ 10:
|foundation = {{start date|2002}}
|___location = [[Saint-Genis-Pouilly]], France
|parent = [[Novartis]]
}}
'''Advanced Accelerator Applications''' ('''AAA''' or '''Adacap''') is a [[France]]-based [[pharmaceutical]] group, specialized in the field of [[nuclear medicine]].<ref name="AAA1">[http://www.privateequitywire.co.uk/2014/02/18/197348/advanced-accelerator-applications-completes-eur41m-fundraising PrivateEquityWire, "Advanced Accelerator Applications completes fundraising", Feb 18th, 2014]</ref>
The group operates in all three segments of nuclear medicine ([[Positron emission tomography|PET]], [[SPECT]] and [[radionuclide therapy|therapy]]) to diagnose and treat serious conditions in the fields of [[oncology]], [[neurology]], [[cardiology]], infectious and inflammatory [[diseases]].<ref name="AAA2">[http://www.ilsole24ore.com/art/impresa-e-territori/2014-03-12/dal-cern-biopark-canavese-064227.shtml?uuid=ABvohR2&fromSearch Il Sole 24 Ore, "Dal Cern and Biopark canavese", March 12th, 2014]</ref>
In late October 2017, ''[[Reuters]]'' announced that [[Novartis]] would acquire the company for $3.9 billion, paying $41 per ordinary share and $82 per American depositary share representing a 47 percent premium.<ref>{{Cite news|url=http://uk.reuters.com/article/uk-novartis-advanced-accelerator/novartis-to-buy-frances-advanced-accelerator-for-3-9-billion-idUKKBN1CZ0KM|archive-url=https://web.archive.org/web/20201205154247/https://uk.reuters.com/article/uk-novartis-advanced-accelerator/novartis-to-buy-frances-advanced-accelerator-for-3-9-billion-idUKKBN1CZ0KM|url-status=dead|archive-date=December 5, 2020|title = Novartis to buy French cancer specialist AAA for $3.9 billion|newspaper = Reuters|date = 3 November 2017|last1 = Miller|first1 = John}}</ref> On January 22, 2018, Novartis AG
==History==
Line 20 ⟶ 22:
AAA currently has a total of 31 sites in 12 countries, including: 19 production facilities in 8 countries (in Europe and the U.S.) that manufacture targeted radioligand therapies and precision imaging radioligands, and 6 sites with R&D activity.
In October 2017, Novartis announced that it intended to acquire the company for US$3.9 billion.<ref>{{Cite web |last=Wirtschaftswoche |title=Advanced Accelerator Applications: Novartis kauft Krebsspezialisten für 3,9 Milliarden Dollar |url=https://www.wiwo.de/unternehmen/industrie/advanced-accelerator-applications-novartis-kauft-krebsspezialisten-fuer-3-9-milliarden-dollar/20520264.html |access-date=2022-08-20 |website=www.wiwo.de |date=30 October 2017 |language=de}}</ref><ref>{{Cite news |last=Larsen |first=Peter Thal |date=2017-10-30 |title=Novartis Makes a Deal That Should Go Down Easy |url=https://www.nytimes.com/2017/10/30/business/dealbook/novartis-advanced-accelerator-applications.html |access-date=2024-08-26 |work=The New York Times |language=en-US |issn=0362-4331}}</ref> The acquisition was completed in January 2018.<ref>{{Cite web |title=Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period |url=https://www.novartis.com/news/media-releases/novartis-completes-tender-offer-advanced-accelerator-applications-sa-and-announces-commencement-subsequent-offering-period |access-date=2024-08-26 |website=Novartis |language=en}}</ref>
In January 2024, AAA announced plans to expand manufacturing capabilities and build additional RLT supply facilities in Sasayama, Japan, and Haiyan, Zhejiang, China.<ref>{{Cite web |last=Staff |first=G. E. N. |date=2024-01-24 |title=Novartis Automates New Radioligand Therapy Production Plant |url=https://www.genengnews.com/topics/bioprocessing/novartis-automates-new-radioligand-therapy-production-plant/ |access-date=2024-08-26 |website=GEN - Genetic Engineering and Biotechnology News |language=en-US}}</ref>
In August 2024, Siemens Healthineers bought the diagnostic arm of Advanced Accelerator Applications that specialises in producing radioactive chemicals used for cancer scan for more than $224 million.<ref>{{Cite web |title=Siemens Healthineers boosts cancer imaging with €200mn Novartis deal |url=https://www.ft.com/content/4a1cf48b-5d55-4e54-8ed6-018b86a6589d?accessToken=zwAAAZGNq7qSkc9KHPSLXVVOVNOO1gGLhqZYnQ.MEQCIBJEdWwU2600r3GB8rJ6-Qas9nWeZqNmDTCnUa0K_HyqAiA2aDmMEZpgsolmVHMfV60y1ifOCnpFZ0yQIokZUHPoTA&segmentId=e95a9ae7-622c-6235-5f87-51e412b47e97&shareType=enterprise&shareId=58f4a850-09e6-46b3-8a7e-bc70ee45432b |access-date=2024-08-26 |website=www.ft.com}}</ref>
==Products==
Line 33 ⟶ 41:
==== Approval ====
Lutathera, also known as [[lutetium]] Lu 177 dotatate, is a target treatment drug for patients with [[Neuroendocrine tumor|GEP-NETs]].<ref name=":0">{{Cite web|url=https://www.cancer.gov/news-events/cancer-currents-blog/2018/lutathera-fda-gastrointestinal-nets|title=FDA Approves New Treatment for Neuroendocrine Tumors|website=National Cancer Institute|date=8 February 2018|language=en|access-date=2018-05-26}}</ref> Its approval for Advanced Accelerator Applications was announced on January 26, 2018, by the [[Food and Drug Administration|US Food and Drug Administration]].<ref name=":1">{{Cite web|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm594043.htm|archive-url=https://web.archive.org/web/20180128055839/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm594043.htm|url-status=dead|archive-date=January 28, 2018|title=Press Announcements - FDA approves new treatment for certain digestive tract cancers|last=Commissioner|first=Office of the|website=www.fda.gov|language=en|access-date=2018-05-26}}</ref> Lutathera is most notable as the first FDA approved peptide receptor [[radionuclide]] therapy (PRRT) to combat GEP-NETs.<ref name=":2">{{Cite web|url=https://www.novartis.com/news/media-releases/advanced-accelerator-applications-receives-fda-approval-lutatherar-treatment-gastroenteropancreatic-neuroendocrine-tumors|title=Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors {{!}} Novartis|website=Novartis|language=en|access-date=2018-05-26}}</ref>
===== GEP-NETs =====
Line 187 ⟶ 195:
==== Advances ====
Lutathera is a major technological advancement for the detection of tumors. [[Diagnostic imaging]] that relies on dotatates can now rely on Lutathera to locate somatostatin receptor-positive tumors by tagging them with its radioactive component.<ref name=":0" /> This tagging of tumors will allow them to become more visible during [[PET radiotracer|positron emission tomography]] (PET) scans.<ref name=":0" /> With LU-177 dotatates, more somatostatin receptor-positive GEP-NET patients can be identified for treatment of the disease.<ref name=":0" />
=== LysaKare ===
LysaKare received a marketing authorisation valid throughout the EU on 25 July 2019.<ref name="LysaKare EPAR">{{cite web | title=LysaKare EPAR | website=[[European Medicines Agency]] (EMA) | date=26 August 2024 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/lysakare | access-date=26 August 2024 }}{{PD-notice}}</ref>
LysaKare protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called lutetium (177Lu) oxodotreotide. LysaKare is for use in adults and contains the active substances arginine and lysine.<ref name="LysaKare EPAR"/>
==Pipeline==
| |||